Full-Time

Senior Manager

Market Access & Reimbursement

Posted on 1/28/2025

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

501-1,000 employees

Develops RNAi-based therapies for diseases

Compensation Overview

$150k - $180kAnnually

Senior

Pasadena, CA, USA

The position is based fully onsite at Arrowhead’s Corporate Headquarters in Pasadena, CA.

Category
Public Health
Biology & Biotech
Required Skills
Marketing
Data Analysis
Requirements
  • Bachelor's degree.
  • 2+ years of access marketing, market access, or healthcare reimbursement experience, including pharmacy and medical benefit products and specialty pharmacy channel.
  • Benefit verification, prior authorization, and denial management.
  • Experience developing marketing plans, navigating MRL reviews, and managing multiple external agencies.
  • Strong skills in project management, collaboration, and stakeholder communication.
  • Ability to work independently while fostering a collaborative team environment.
Responsibilities
  • Support the development of innovative and impactful initiatives and tactics that align to the Patient Services Program (PSP) strategic imperatives.
  • Manage copay and coinsurance programs, including patient affordability support.
  • Provide primary account management for third-party program sponsors.
  • Collaborate with vendors to establish SOPs and streamline patient affordability services.
  • Partner with Marketing to create materials and resources for HCPs, office staff, patients, and caregivers focused on access and reimbursement.
  • Analyze program data to drive improvements, monitor KPIs, and manage dashboard metrics.
  • Support PSP brand positioning by identifying barriers to patient access and implementing innovative solutions.
  • Manage agency partnerships, including creative and data teams to execute impactful initiatives.
  • Assist in market access budget management, optimizing resources, and identifying efficiencies.
  • Draft market access briefs, set project timelines, and address potential barriers.
Desired Qualifications
  • Launch experience, cardiometabolic/rare disease preferred.
  • Master’s / Advanced Degree (MBA, MPH, PharmD).
Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

View

Arrowhead Pharmaceuticals develops medicines aimed at treating severe diseases by targeting and silencing specific genes. The company uses RNA interference (RNAi), a natural process that reduces gene expression, to create therapies that can potentially stop or reverse the progression of diseases like cystic fibrosis and hepatitis B. Their approach involves a variety of RNA chemistries and effective delivery methods to ensure deep and lasting effects on target genes. Unlike many competitors, Arrowhead focuses specifically on RNAi-based therapies, which allows them to address medical needs that are not met by existing treatments. Their goal is to provide new options for patients suffering from genetic disorders, and they generate revenue through partnerships, licensing agreements, and future sales of their therapies after regulatory approval.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Pasadena, California

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Strategic financing with Sixth Street accelerates RNAi therapy development and commercialization.
  • Collaboration with Sarepta Therapeutics expands market reach for rare genetic disease treatments.
  • Positive Phase 2 data for plozasiran strengthens Arrowhead's position in hypertriglyceridemia treatment.

What critics are saying

  • Increased competition from companies like Alnylam Pharmaceuticals may impact market share.
  • Regulatory scrutiny could delay clinical trials and affect drug approval timelines.
  • Reliance on strategic financing may lead to increased debt obligations.

What makes Arrowhead Pharmaceuticals unique

  • Arrowhead uses RNAi to target and silence disease-causing genes effectively.
  • The company has a broad portfolio of RNA chemistries for diverse therapeutic applications.
  • Arrowhead's proprietary delivery methods ensure rapid and durable gene knockdown.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Paid Vacation

Paid Sick Leave

Company News

PharmaData
Mar 1st, 2025
Arrowhead Pharmaceuticals Launches FCS Patient Resources on Rare Disease Day

Arrowhead Pharmaceuticals launches FCS patient resources on Rare Disease Day.

Business Wire
Feb 28th, 2025
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

New Patient Resource Hub: Arrowhead expands its We'll Get There Soon campaign with the launch of a dedicated patient website, providing education, tools, and support for those living with FCS and extremely high triglycerides

World Pharmaceuticals
Nov 29th, 2024
Dev4All and Pharmaseed enter commercial partnership for preclinical R&D

Recently, Arrowhead Pharmaceuticals and Sarepta Therapeutics signed a global licensing and collaboration agreement to develop clinical and preclinical programmes.

BioSpace
Nov 26th, 2024
Sarepta Aims Up to $10B at Arrowhead to Diversify Pipeline With RNA Drugs

Sarepta Therapeutics is putting massive biobucks on the line to work on RNA drugs with Arrowhead, paying out $500 million upfront to find new treatments for rare genetic diseases of the muscle, central nervous system and lung.

Endpoints News
Aug 14th, 2024
Arrowhead lays out early-stage obesity strategy, including new target on fat-storing cells

Arrowhead Pharmaceuticals unveiled a new RNAi-based obesity program on Wednesday that it believes could be "gentler" than currently available GLP-1 products...

INACTIVE